BCLI vs. ELEV, PASG, CVM, GRCE, LIAN, TENX, KALA, JATT, CALC, and FNCH
Should you be buying Brainstorm Cell Therapeutics stock or one of its competitors? The main competitors of Brainstorm Cell Therapeutics include Elevation Oncology (ELEV), Passage Bio (PASG), CEL-SCI (CVM), Grace Therapeutics (GRCE), LianBio (LIAN), Tenax Therapeutics (TENX), KALA BIO (KALA), JATT Acquisition (JATT), CalciMedica (CALC), and Finch Therapeutics Group (FNCH). These companies are all part of the "pharmaceutical products" industry.
Brainstorm Cell Therapeutics vs.
Brainstorm Cell Therapeutics (NASDAQ:BCLI) and Elevation Oncology (NASDAQ:ELEV) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their analyst recommendations, earnings, institutional ownership, risk, dividends, media sentiment, valuation, profitability and community ranking.
14.3% of Brainstorm Cell Therapeutics shares are held by institutional investors. Comparatively, 83.7% of Elevation Oncology shares are held by institutional investors. 6.7% of Brainstorm Cell Therapeutics shares are held by insiders. Comparatively, 8.1% of Elevation Oncology shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.
Brainstorm Cell Therapeutics has a beta of 0.6, indicating that its share price is 40% less volatile than the S&P 500. Comparatively, Elevation Oncology has a beta of 1.65, indicating that its share price is 65% more volatile than the S&P 500.
Brainstorm Cell Therapeutics' return on equity of 0.00% beat Elevation Oncology's return on equity.
Brainstorm Cell Therapeutics currently has a consensus target price of $30.00, indicating a potential upside of 2,207.69%. Elevation Oncology has a consensus target price of $3.39, indicating a potential upside of 811.12%. Given Brainstorm Cell Therapeutics' stronger consensus rating and higher probable upside, equities research analysts plainly believe Brainstorm Cell Therapeutics is more favorable than Elevation Oncology.
Brainstorm Cell Therapeutics received 252 more outperform votes than Elevation Oncology when rated by MarketBeat users. However, 66.10% of users gave Elevation Oncology an outperform vote while only 59.39% of users gave Brainstorm Cell Therapeutics an outperform vote.
In the previous week, Brainstorm Cell Therapeutics had 2 more articles in the media than Elevation Oncology. MarketBeat recorded 5 mentions for Brainstorm Cell Therapeutics and 3 mentions for Elevation Oncology. Elevation Oncology's average media sentiment score of 0.72 beat Brainstorm Cell Therapeutics' score of 0.17 indicating that Elevation Oncology is being referred to more favorably in the news media.
Elevation Oncology is trading at a lower price-to-earnings ratio than Brainstorm Cell Therapeutics, indicating that it is currently the more affordable of the two stocks.
Summary
Elevation Oncology beats Brainstorm Cell Therapeutics on 8 of the 15 factors compared between the two stocks.
Get Brainstorm Cell Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for BCLI and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Brainstorm Cell Therapeutics Competitors List
Related Companies and Tools
This page (NASDAQ:BCLI) was last updated on 5/1/2025 by MarketBeat.com Staff
Buy BCLI Stock Free BCLI Stock Alerts